Rxsight Inc (RXST) Q1 2026 Earnings Call Transcript

Why It Matters

The shift toward higher‑margin LAL sales underscores RxSight’s strategic pivot in the premium IOL market, while guidance signals near‑term revenue pressure and the need for disciplined cost management.

Key Takeaways

• Q4 sales $32.6M, down 19% YoY.
• LAL accounts for 86% of revenue, boosting margin.
• Gross margin 77.5%, highest quarter yet.
• 2026 revenue forecast $120‑135M, implying ~5% decline.
• Cash $228M, no debt, strong liquidity.

Pulse Analysis

RxSight’s earnings spotlight a decisive transition from its Light Delivery Device (LDD) platform to the Light Adjustable Lens (LAL) as the primary growth engine. By capturing 86% of quarterly sales, the LAL not only stabilizes revenue amid volatile device placements but also drives gross margins above 77%, a notable premium over traditional intraocular lenses. This margin expansion reflects the market’s willingness to pay for postoperative adjustability, positioning RxSight at the forefront of the premium IOL segment where visual precision and patient satisfaction command higher reimbursement rates.

Looking ahead, the company’s 2026 outlook balances optimism with caution. Revenue guidance of $120‑135 million suggests a modest 5% decline, largely attributed to anticipated lower LDD volumes and higher‑cost inventory absorption that compresses gross margins to 70‑72%. Operating expenses are projected between $150‑160 million, with R&D spending holding steady, indicating continued investment in pipeline innovations despite tighter cash flows. International expansion remains deliberately incremental, with early capital placements expected to contribute minimally this year, underscoring a strategic focus on building KOL relationships before scaling abroad.

Clinical validation continues to reinforce the LAL’s value proposition. A recent study showed 93% of treated eyes achieving refractive targets within half a diopter, outperforming conventional toric lenses and bolstering the case for premium pricing. Coupled with a robust pipeline of FDA‑approved enhancements, RxSight is poised to leverage its strong liquidity position to fund further product development and market education. As cataract surgery trends shift toward myopia correction and earlier interventions worldwide, the company’s adjustable technology could capture a growing share of the global premium IOL market, provided it navigates inventory challenges and sustains its clinical momentum.